Corcept Therapeutics Incorporated

    Jurisdiction
    United States
    LEI
    529900EO9LUTFMZ7FF90
    ISIN
    US2183521028 (CORT)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    60 / 100
    Better than peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    €117.80 55.6% undervalued
    Financial strength (Piotroski F-Value)
    6 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. Read full profile

    Fundamentals

    Net revenue
    €610.78M
    Gross margin
    98.4%
    EBIT
    €86.96M
    EBIT margin
    14.2%
    Net income
    €113.03M
    Net margin
    18.5%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €981.36M +60.7% €212.36M +87.9%
    €1.49B +51.9% €604.64M +184.7%
    €1.92B +28.9% €945.46M +56.4%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    BELANOFF JOSEPH K Chief Executive Officer -40K $70.53 -$2.82M
    Guyer William Chief Development Officer -20K $70.49 -$1.41M
    Lyon Joseph Douglas See Remarks -5K $70.25 -$351.25K
    Maduck Sean See Remarks -20K $70.49 -$1.41M
    Robb Gary Charles Chief Business Officer -2.3K $71.27 -$165.77K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 6.1M $701.66M -56K Sell

    Earnings Calls

    Latest earnings call: May 1, 2024 (Q1 2024)

    Add to watchlist

    Notifications